Second-line antiretroviral therapy: Long-term outcomes in South Africa

Journal of Acquired Immune Deficiency Syndromes

Volumn 61, Issue 2, 2012, Pages 158-163

  Murphy, Richard A ^a   Sunpath, Henry ^b   Castilla, Carmen ^c   Ebrahim, Shameez ^b   Court, Richard ^d   Nguyen, Hoang ^e   Kuritzkes, Daniel R ^c   Marconi, Vincent C ^f   Nachega, Jean B ^g  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b MCCORD HOSPITAL   (South Africa)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UNIVERSITY OF CAPE TOWN   (South Africa)

^e JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^f EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

adherence; resourcelimited settings; second line antiretroviral therapy; South Africa

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DIDANOSINE; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; STAVUDINE; ZIDOVUDINE;

ADULT; AGE; ARTICLE; CD4 LYMPHOCYTE COUNT; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; SEX DIFFERENCE; SOUTH AFRICA; VIRUS INHIBITION; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; CHILD, PRESCHOOL; FEMALE; HIV INFECTIONS; HUMANS; INFANT; MALE; MEDICATION ADHERENCE; RETROSPECTIVE STUDIES; SOUTH AFRICA; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84866983307     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3182615ad1     Document Type: Article

References (22)

1. Marconi VC, Sunpath H, Lu Z, et al. Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. Clin Infect Dis. 2008;46:1589-1597.
2. Kamya MR, Mayanja-Kizza H, Kambugu A, et al. Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy. J Acquir Immune Defic Syndr. 2007;40: 187-193.
3. Hosseinipour MC, van Oosterhout JJ, Weigel R, et al. The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS. 2009;23:1127-1134.
4. Pujades-Rodriguez M, Balkan S, Arnould L, et al. Treatment failure and mortality factors in patients receiving second-line HIV therapy in resource-limited countries. JAMA. 2010;304:303-312.
5. Murphy RA, Sunpath H, Lu Z, et al. Outcomes after virologic failure of first-line ART in South Africa. AIDS. 2010;24:1007-1012.
6. Fox MP, Ive P, Long L, et al. High rates of survival, immune reconsti-tution, and virologic suppression on second-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr. 2010;53:500-506.
7. World Health Organization. World Health Statistics 2011, Geneva, Switzerland: World Health Organization; 2011.
8. Department of Health. The 2010 National Antenatal Sentinel HIV and Syphilis Prevalence Survey in South Africa. Pretoria, South Africa: National Department of Health; 2011.
9. Nel A, Mabude Z, Smit J, et al. HIV incidence remains high in KwaZulu-Natal, South Africa: evidence from three districts. PLoS One. 2012;7:e35278.
10. Bisson GP, Gross R, Bellamy S, et al. Pharmacy refill adherence compared with CD4 count changes for monitoring HIV-infected adults on antiretroviral therapy. PLoS Med. 2008;5:e109.
11. Nachega JB, Hislop M, Dowdy DW, et al. Adherence to highly active antiretroviral therapy assessed by pharmacy claims predicts survival in HIV-infected South African adults. J Acquir Immune Defic Syndr. 2006; 43:78-84.
12. Kumarasamy N, Vallabhaneni S, Cecelia AJ, et al. Reasons for modification of generic highly active antiretroviral therapeutic regimens among patients in southern India. J Acquir Immune Defic Syndr. 2006:53-58.
13. van Oosterhout JJ, Bodasing N, Kumwenda JJ, et al. Evaluation of anti-retroviral therapy results in a resource-poor setting in Blantyre, Malawi. Trop Med Int Health. 2005:464-470.
14. Lathouwers E, De Meyer S, Dierynck I, et al. Virological characterization of patients failing darunavir/ritonavir or lopinavir/ritonavir treatment in the ARTEMIS study: 96-week analysis. Antivir Ther. 2011;16:99-108.
15. Wallis CL, Mellors JW, Venter WD, et al. Protease inhibitor resistance is uncommon in HIV-1 subtype C infected patients on failing second-line lopinavir/r-containing antiretroviral therapy in South Africa. AIDS Res Treat. 2011;2011:769627.
16. van Zyl GU, van Mens TE, McIlleron H, et al. Low lopinavir plasma or hair concentrations explain second-line protease inhibitor failures in a resource-limited setting. J Acquir Immune Defic Syndr. 2011;56: 333-339.
17. Acri T, TenHave TR, Chapman JC, et al. Lack of association between retrospectively collected pharmacy refill data and electronic drug monitoring of antiretroviral adherence. AIDS Behav. 2010;14:748-754.
18. Rougemont M, Stoll BE, Elia N, et al. Antiretroviral treatment adherence and its determinants in Sub-Saharan Africa: a prospective study at Yaounde Central Hospital, Cameroon. AIDS Res Ther. 2009;6:21.
19. Chi BH, Cantrell RA, Zulu I, et al. Adherence to first-line antiretroviral therapy affects non-virologic outcomes among patients on treatment for more than 12 months in Lusaka, Zambia. Int J Epidemiol. 2009;38:746-756.
20. Toure S, Kouadio B, Seyler C, et al. Rapid scaling-up of antiretroviral therapy in 10,000 adults in Cote d'Ivoire: 2-year outcomes and determinants. AIDS. 2008;22:873-882.
21. Ross-Degnan D, Pierre-Jacques M, Zhang F, et al. Measuring adherence to antiretroviral treatment in resource-poor settings: the clinical validity of key indicators. BMC Health Serv Res. 2010;10:42.
22. Nachega JB, Trotta MP, Nelson M, et al. Impact of metabolic complications on antiretroviral treatment adherence: clinical and public health implications. Curr HIV/AIDS Rep. 2009;6:121-129.